Navigation Links
Wellspring Biosciences Founder Publishes In Nature On Discovery of Small Molecule Inhibitors of K-Ras
Date:11/20/2013

LA JOLLA, Calif., Nov. 20, 2013 /PRNewswire/ -- Wellspring Biosciences, a leading biopharmaceutical company focused on the discovery and development of novel drugs for the treatment of cancer, announced today a publication from Kevan Shokat, Ph.D., one of its founders and chairman of its scientific advisory board, in the journal Nature that describes the discovery of small molecules that bind irreversibly to a common oncogenic mutant, K-Ras G12C.

Ras genes are mutated in up to 30% of human cancers and are among the most important therapeutic targets in the treatment of human cancer.  Yet, to date, not a single drug that targets Ras proteins or acts on Ras-driven cancers has been developed successfully.  Indeed, tumors harboring Ras mutations are among the most difficult to treat and are excluded from treatment with many therapies.

Dr. Shokat serves as Professor and Chair in the Department of Cellular and Molecular Pharmacology at UCSF as well as Investigator, Howard Hughes Medical Institute.  "We are extremely excited to find a druggable binding pocket on K-Ras, the most frequently mutated oncogene in human cancer" said Professor Shokat.  "Our findings can serve as the starting point for drug-discovery efforts targeting the G12C form of K-Ras and eventually other cancer causing alleles of K-Ras."

"The proto-oncogene K-Ras is mutated in a wide array of human cancers, most of which are aggressive and respond poorly to standard therapies," said Yi Liu, Ph.D., Chief Scientific Officer of Wellspring Biosciences.  "This represents one of the most promising approaches to target K-Ras yet reported, and we look forward to continuing to advance this exciting science in the potentially transformative area of drug development."

In February 2013, Wellspring Biosciences, through its affiliate Araxes Pharma, entered into an exclusi
'/>"/>

SOURCE Wellspring Biosciences LLC
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology news :

1. Springer will publish lecture series with the Mathematical Biosciences Institute
2. Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation
3. Inflection Biosciences licenses preclinical oncology programs from the CNIO
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
6. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
7. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
8. Alfred Russel Wallace: Co-founder of the theory of biological evolution
9. Google, Intel founders support undersea research by UMass Amherst microbiologist
10. Dr. Anurag Agrawal to give Founders Memorial lecture at Entomology 2013
11. Biophysical Society names 2013 Distinguished Service, Emily M. Gray, and Founders awardees
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4
... technical, managerial and financial components of healthcare delivery to ... Disease) patient will be the topic of Stevens Institute ... October 31, 2007, from 3-5 p.m. in Room 122 ... Streets in Hoboken, NJ). , Roundtable participants will discuss ...
... a 46 percent increase in lifespan, raising the tantalizing ... are also taking an anti-aging medication. Results of the ... Lithgow, PhD, are currently published online in the Journal ... to treat mood affective disorders, including bipolar disease for ...
... daily commute may be taking more of a toll than ... of Southern California (USC) and the California Air Resources Board ... exposure to harmful air pollutants occurs while people are traveling ... spends about six percent (1.5 hours) of his or her ...
Cached Biology News:Stevens Health, Technology, and Society roundtable: Oct. 31 2Drug commonly used to treat bipolar disorder dramatically increases lifespan in worms 2Time spent in car drives up air pollution exposure 2
(Date:12/19/2014)... LayerBio is an MIT spin-off developing novel ... National Eye Institute (NEI) at the National Institutes of ... grant to develop a drug-eluting intraocular lens (IOL) for ... of vision loss in people over age 40 and ... Ken Mandell, LayerBio’s Founder and CEO, "There is a ...
(Date:12/19/2014)... December 19, 2014 The empty ... the rising ageing population and technological innovations in ... nutraceutical industries are catalysing the growth of the ... http://www.marketsandmarkets.com/Market-Reports/empty-capsules-market-218018190.html , Scope of Report , ... well as new entrants/smaller firms to gauge the ...
(Date:12/19/2014)... Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage ... pain, announced the results of its annual general meeting ... transformational year in Relmada,s history and it set the ... Sergio Traversa , chief executive officer of Relmada. ... financial, human resource and clinical development objectives that position ...
(Date:12/17/2014)... Ipsen Biopharmaceuticals, Inc., an affiliate ... IPSEY), today announced that Somatuline® Depot® (lanreotide) ... approved by the U.S. Food and Drug Administration ... (GEP-NETs) in adult patients with unresectable, well or ... improve progression-free survival (PFS). , “The approval of ...
Breaking Biology Technology:LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 2Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 3Empty Capsules Market Hit to Reach $1,820 Million by 2019 - New Research Report by MarketsandMarkets 4Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 2Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 3Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 4Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 5Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 6Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 7Ipsen Announces the FDA Approval of Somatuline® Depot® (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors 8
... DIEGO, INDIANAPOLIS and WALTHAM, Mass., March 10, 2011 ... Lilly and Company (NYSE: LLY ) and ... positive results from a phase 2 study evaluating the ... on glycemic control in patients with type 2 diabetes. ...
... 2011 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... a randomized pivotal trial of pixantrone for the treatment ... the  U.S. Food and Drug Administration,s (the "FDA") Division ... trial, referred to as the PIX-R or PIX 306 ...
... release is available in German . , From the ... to the strings and sound box of a guitar or violin, ... actual mechanical vibrations of these instruments create acoustic waves that we ... related to the decay of the vibration amplitude, that is, the ...
Cached Biology Technology:Exenatide Once Monthly Showed Positive Results in Phase 2 Study 2Exenatide Once Monthly Showed Positive Results in Phase 2 Study 3Exenatide Once Monthly Showed Positive Results in Phase 2 Study 4Exenatide Once Monthly Showed Positive Results in Phase 2 Study 5Exenatide Once Monthly Showed Positive Results in Phase 2 Study 6Exenatide Once Monthly Showed Positive Results in Phase 2 Study 7FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 2FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 3FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 4FDA Provides Guidance for Design of Cell Therapeutics' Pixantrone Pivotal Trial 5How long does a tuning fork ring? 2
Rabbit polyclonal to Factor IX ( Abpromise for all tested applications). entrezGeneID: 2158 SwissProtID: P00740...
Adhesion Molecule Antibodies...
Rabbit polyclonal to Glutathione S Transferase alpha ( Abpromise for all tested applications). Antigen: Full length protein: Human Glutathione S Transferase alpha. Entrez GeneID: 2938 Swi...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
Biology Products: